Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Conspicuous Consumption: TB Therapies Are A Priority At FDA

Executive Summary

A June 3 advisory committee discussion of tuberculosis drug development offers a good early case study of how the Hamburg FDA may benefit some classes of drug development

You may also be interested in...



TB Study Lights Pathway Toward Combination Drug Trial Guidance

A clinical trial of three new tuberculosis drugs, along with one that is used in standard therapy, exemplifies FDA's evolving approach to studies that combine more than one investigational drug.

TB Study Lights Pathway Toward Combination Drug Trial Guidance

A clinical trial of three new tuberculosis drugs, along with one that is used in standard therapy, exemplifies FDA's evolving approach to studies that combine more than one investigational drug.

Tuberculosis Trial Design: FDA/Company Endpoint Talks Go Public At Cmte.

The approval pathway for drugs to treat multi-drug resistant tuberculosis became somewhat clearer for sponsors as FDA's Anti-Infective Drugs Advisory Committee weighed in on clinical trial endpoints at a June 3 meeting

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel